학술논문
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients
Document Type
Article
Author
Source
In Clinical Lung Cancer May 2018 19(3):e361-e372
Subject
Language
ISSN
1525-7304